ESMO 2026 - KEYNOTE-B49: Who May Benefit? With Dr. Hope Rugo

Could immunotherapy have a role in endocrine-resistant HR+/HER2-negative advanced breast cancer? Dr. Hope Rugo shares the KEYNOTE-B49 findings and what they could mean for patient selection and clinical practice.